| Robert J Mcdonald, MD | |
|
170 Grandview Avenue, Waterbury, CT 06708 | |
| (203) 759-3666 | |
| (203) 759-3671 |
| Full Name | Robert J Mcdonald |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 36 Years |
| Location | 170 Grandview Avenue, Waterbury, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023125549 | NPI | - | NPPES |
| 1382259 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 038225 (Connecticut) | Secondary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | 38225 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Waterbury Hospital | Waterbury, CT | Hospital |
| Saint Mary's Hospital | Waterbury, CT | Hospital |
| Carson Tahoe Regional Medical Center | Carson city, NV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prospect Ct Medical Foundation Inc | 7416244496 | 267 |
News Archive
The critical care doctor Julio Barado-Hualde (Villava, Navarre, 1965) has developed a mathematical simulation model that enables the occupancy of beds in an ICU (Intensive Care Unit) to be predicted so that they can be managed more effectively. This research, which focusses on the Hospital Complex of Navarre, is part of his PhD thesis read at the NUP/UPNA-Public University of Navarre.
ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New Drug (IND) application for the company's lead product candidate, AGT-182 for the treatment of Hunter syndrome, has been accepted by the U.S. Food and Drug Administration and is now active.
Researchers at The Wistar Institute have found that combining PARP inhibitors, recently approved for the treatment of BRCA-mutant ovarian cancer, with another small molecule inhibitor was effective to treat ovarian cancers without BRCA1 and BRCA2 gene mutations.
A clinical trial of patients with post-acute coronary syndrome (ACS, heart disease) depression finds that a centralized, patient-preference program decreased depressive symptoms and may be cost-neutral over time, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.
Antifibrinolytic drugs are frequently used to prevent blood loss during surgery, but sometimes cause convulsive seizures. In this issue of the Journal of Clinical Investigation, researchers led by Beverly Orser at the University of Toronto investigated the molecular mechanisms that underlie this side effect.
› Verified 6 days ago
| Entity Name | Waterbury Pulmonary Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669501532 PECOS PAC ID: 4082710306 Enrollment ID: O20070503000246 |
News Archive
The critical care doctor Julio Barado-Hualde (Villava, Navarre, 1965) has developed a mathematical simulation model that enables the occupancy of beds in an ICU (Intensive Care Unit) to be predicted so that they can be managed more effectively. This research, which focusses on the Hospital Complex of Navarre, is part of his PhD thesis read at the NUP/UPNA-Public University of Navarre.
ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New Drug (IND) application for the company's lead product candidate, AGT-182 for the treatment of Hunter syndrome, has been accepted by the U.S. Food and Drug Administration and is now active.
Researchers at The Wistar Institute have found that combining PARP inhibitors, recently approved for the treatment of BRCA-mutant ovarian cancer, with another small molecule inhibitor was effective to treat ovarian cancers without BRCA1 and BRCA2 gene mutations.
A clinical trial of patients with post-acute coronary syndrome (ACS, heart disease) depression finds that a centralized, patient-preference program decreased depressive symptoms and may be cost-neutral over time, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.
Antifibrinolytic drugs are frequently used to prevent blood loss during surgery, but sometimes cause convulsive seizures. In this issue of the Journal of Clinical Investigation, researchers led by Beverly Orser at the University of Toronto investigated the molecular mechanisms that underlie this side effect.
› Verified 6 days ago
| Entity Name | Prospect Ct Medical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144677568 PECOS PAC ID: 7416244496 Enrollment ID: O20160919001322 |
News Archive
The critical care doctor Julio Barado-Hualde (Villava, Navarre, 1965) has developed a mathematical simulation model that enables the occupancy of beds in an ICU (Intensive Care Unit) to be predicted so that they can be managed more effectively. This research, which focusses on the Hospital Complex of Navarre, is part of his PhD thesis read at the NUP/UPNA-Public University of Navarre.
ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New Drug (IND) application for the company's lead product candidate, AGT-182 for the treatment of Hunter syndrome, has been accepted by the U.S. Food and Drug Administration and is now active.
Researchers at The Wistar Institute have found that combining PARP inhibitors, recently approved for the treatment of BRCA-mutant ovarian cancer, with another small molecule inhibitor was effective to treat ovarian cancers without BRCA1 and BRCA2 gene mutations.
A clinical trial of patients with post-acute coronary syndrome (ACS, heart disease) depression finds that a centralized, patient-preference program decreased depressive symptoms and may be cost-neutral over time, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.
Antifibrinolytic drugs are frequently used to prevent blood loss during surgery, but sometimes cause convulsive seizures. In this issue of the Journal of Clinical Investigation, researchers led by Beverly Orser at the University of Toronto investigated the molecular mechanisms that underlie this side effect.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert J Mcdonald, MD 170 Grandview Avenue, Waterbury, CT 06708 Ph: (203) 759-3666 | Robert J Mcdonald, MD 170 Grandview Avenue, Waterbury, CT 06708 Ph: (203) 759-3666 |
News Archive
The critical care doctor Julio Barado-Hualde (Villava, Navarre, 1965) has developed a mathematical simulation model that enables the occupancy of beds in an ICU (Intensive Care Unit) to be predicted so that they can be managed more effectively. This research, which focusses on the Hospital Complex of Navarre, is part of his PhD thesis read at the NUP/UPNA-Public University of Navarre.
ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New Drug (IND) application for the company's lead product candidate, AGT-182 for the treatment of Hunter syndrome, has been accepted by the U.S. Food and Drug Administration and is now active.
Researchers at The Wistar Institute have found that combining PARP inhibitors, recently approved for the treatment of BRCA-mutant ovarian cancer, with another small molecule inhibitor was effective to treat ovarian cancers without BRCA1 and BRCA2 gene mutations.
A clinical trial of patients with post-acute coronary syndrome (ACS, heart disease) depression finds that a centralized, patient-preference program decreased depressive symptoms and may be cost-neutral over time, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.
Antifibrinolytic drugs are frequently used to prevent blood loss during surgery, but sometimes cause convulsive seizures. In this issue of the Journal of Clinical Investigation, researchers led by Beverly Orser at the University of Toronto investigated the molecular mechanisms that underlie this side effect.
› Verified 6 days ago
Dr. Juan Fica, M.D. Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 1389 W Main St, Tower 2, Suite 320, Waterbury, CT 06708 Phone: 203-753-9313 Fax: 203-573-8976 | |
Mrs. Kanthimathi Jegathesan, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2271 East Main Street, Waterbury, CT 06705 Phone: 203-753-4131 Fax: 203-753-6887 | |
Dr. Lydia Aoun-barakat, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 140 Grandview Ave, Suite #l01, Waterbury, CT 06708 Phone: 203-574-4187 Fax: 203-591-1453 | |
David G. Hill, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 170 Grandview Avenue, Waterbury, CT 06708 Phone: 203-759-3666 Fax: 203-759-3671 | |
Shehryar Khaliqdina, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 56 Franklin St, Waterbury, CT 06706 Phone: 203-709-8685 | |
Dr. Joseph D Scuderi, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 56 Franklin St, Waterbury, CT 06706 Phone: 203-709-6000 |